Preview

Пульмонология

Расширенный поиск

Новые возможности антигистаминных препаратов (внимание на фексофенадин)

Полный текст:

Об авторе

А. С. Соколов
НИИ пульмонологии М3 РФ
Россия

Москва



Список литературы

1. Barnett A. , Kreutner W. Pharmacology of non-sedating Hj antihistamines / / New Perspectives in Histamine Research.— Basel: Birkhauser Verlag, 1991.— P. 181 — 196.

2. Bernstein D.I., Schoenwetter W.F., Nathan R.A., et. al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis// Ann. Allergy Asthma Immunol.— 1997.— Vol. 79.— P.443—448.

3. Bronsky E.A., Falliers C.J., Kaiser H.B., et. al. Effectiveness and safety of fexofenadine, a new nonsedating H|-receptor antagonist, in the treatment of fall allergies// Allergy Asthma Proc.— 1998.— Vol. 19.— P. 135— 141.

4. Chowdhury B.A. Kaliner M.A. Molecular identification of the histamine Hj receptor in humans// Simons F.E.R., ed. Histamine and H,-Receptor Antagonists in Allergic Disease.— New York: Marcel Dekker, 1996.— P.33— 60.

5. DuBuske L.M. Clinical comparison of histamine H r receptor antagonist drugs// J.Allergy Clin. Immunol.— 1996.— Vol. 98.— P.307—318

6. Hill S.J. Distribution, properties, and functional characteristic of three classes of histamine receptor// Pharmacol Rev.— 1990.— Vol. 42.— P.45—83.

7. Horton M.W., Swan S.K., Halstenson C.E. et al. Pharmacokinetics of fexfenadine in patients with varying degrees of renal impairment// Pharm. Res.— 1996.— Vol. 13.— Suppl.—S431.

8. Howarth P.H., Sterrn M.A., Roi L. et al. Double—blind, placebo—controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis// J. Allergy Clin. Immunol.— 1999.— Vol.104.— P.927—933.

9. Lippert C.L., Rao N., Eller M.G., Weir S.J. Pharmacokinetics of fexfenadine in liver diseased patients// Pharm. Res.— 1996.— Vol. 13.— Suppl.— S431.

10. Markham A., Wagstaff A.J. Fexofenadine// Drugs.— 1998.— Vol. 55.— P.269—274.

11. Mason J., Reynolds R., Rao N. The systemic safety of fexofenadine H C L// Clin. Exp. Allergy.— 1999.— Vol. 29.— Suppl. 3.— P.163—170.

12. Meitzer E.O., Welch M.J. Adverse effects of HI-receptor antagonists in the central nervous sistem// Simons F.E.R., ed. Histamine and Hj-Receptor Antagonists in Allergic Disease.— New York: Marcel Dekker, 1996.— P. 33—60.

13. Metcalfe D.D. Effector cell heterogenety in immediate hypersensivity reactions// Clin. Rev. Allergy.— 1983.— Vol. 1.— P.311—325.

14. Pratt C., Mason J., Russell Т., Ahlbrandt R. Effect of fexofenadine on corrected QT interval (Qtc) ¡Abstract]// Allergy.— 1997.— Vol. 52.— Suppl. 37.— P.67.

15. Simons F.E.R , Jonts K.J. The pharmacology and use of H r receptor-antagonist drugs// N. Engl.J. Med.— 1994.— Vol. 330.— P. 1663— 1670.

16. Simons F.E.R, Bergman J.N., Watson W.T.A., Simons K.J. The clinical pharmacology of fexofenadine in children// J. Allergy Clin. Immunol.— 1996.— Vol. 98.— P.1062—1064.

17. Simons F.E.R , Simons K.J. Peripheral H r blockade effect of fexofenadine/ / Ann. Allergy Asthma Immunol.— 1997.— Vol. 79.— P.530—532.

18. White M.V., Kaliner M.A. Histamine in allergic diseases//Simons F.E.R., ed. Histamine and H r Receptor Antagonists in Allergic Disease.— New York: Marcel Dekker, 1996.— P. 61—91

19. Woosley R.L., Chen Y.,Freiman J.P., Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine// J.A.M.A.— 1993.— N. 26.— P.1532—1536.


Для цитирования:


Соколов А.С. Новые возможности антигистаминных препаратов (внимание на фексофенадин). Пульмонология. 2000;(2):74-78.

For citation:


Sokolov A.S. New abilities of anti-histamine drugs. PULMONOLOGIYA. 2000;(2):74-78. (In Russ.)

Просмотров: 1


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)